CLEO DIAGNOSTICS LTD — Share Issue/Capital Change 2026

May 27, 2026

ASX Announcement
28 May 2026
CLEO
DIAGNOSTICS

NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001

(a) The Company has issued 250,000 fully paid ordinary shares (Shares) in the Company.
(b) The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.
(c) As at the date of this notice, the Company has complied with:
- the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and
- sections 674 and 674A of the Corporation Act.
(d) As at the date of this notice, there is no 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) required to be disclosed under section 708A(6)(e) of the Corporations Act.

Released with the authority of the Board.

Pauline Moffatt
Company Secretary

Cleo Diagnostics Ltd ASX:coV
Level 2, 480 Collins Street, Melbourne, VIC, 3000
ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com
Directors
Chair and Non-Executive Director Adnan Wing
Chief Executive Officer and Executive Director Dr Richard Allman
Chief Scientific Officer and Executive Director Dr Andrew Stephens
Non-Executive Director and Lead Medical Advisor Professor Tom Jobling
Non-Executive Director Lucinda Nolan
cleodx.com